BHP will not make a fresh bid for Anglo American in the near term, FT reports-March 2024-www.financetom.com

BHP will not make a fresh bid for Anglo American in the near term, FT reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BHP will not make a fresh bid for Anglo American in the near term, FT reports

Jan 24, 2025 11:50 PM

Jan 25 (Reuters) - Australia's BHP will not be

making a fresh bid for rival miner Anglo American in the

near term because its shares have become too expensive, the

Financial Times reported on Saturday, citing three people close

to the situation.

Previous page： --Bank7 Ups Quarterly Dividend to $0.24 a Share From $0.21, Payable Oct. 9 to Holders of Record Sept. 26 Next page： US charges Citron's Andrew Left over alleged multi-million fraud scheme

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Bank7 Ups Quarterly Dividend to $0.24 a Share From $0.21, Payable Oct. 9 to Holders of Record Sept. 26

Jul 26, 2024

10:24 AM EDT, 07/26/2024 (MT Newswires) -- Price: 40.93, Change: +0.61, Percent Change: +1.51 ...

US charges Citron's Andrew Left over alleged multi-million fraud scheme

Jul 26, 2024

July 26 (Reuters) - U.S. authorities filed criminal and civil charges against prominent activist short seller Andrew Left for an alleged long-running market manipulation scheme involving bets on stocks including Nvidia ( NVDA ) and Tesla , they said on Friday. Left used his Citron Research website and social media platforms to recommend long or short positions in 23 companies,...

Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events

Jul 26, 2024

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the approval of Eisai Co., Ltd ( ESALF ) (OTC:ESALF) and Biogen Inc.’s lecanemab. The companies seek approval for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody as a treatment for early AD (mild cognitive impairment due to...

3M Raises Low End of 2024 Earnings Outlook as Second-Quarter Results Top Views

Jul 26, 2024

10:18 AM EDT, 07/26/2024 (MT Newswires) -- 3M ( MMM ) lifted the low end of its full-year earnings outlook on Friday after reporting second-quarter results above market estimates. The industrial conglomerate now expects adjusted earnings of $7 to $7.30 per share for 2024, compared with a $6.80 bottom end of its prior guidance range. The consensus among analysts on...